Patents by Inventor Christopher R. Behrens

Christopher R. Behrens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PURIFICATION PROCESSES FOR POLYSACCHARIDES AND POLYPEPTIDE CONJUGATES THEREOF
    Publication number: 20240000926
    Abstract: The present disclosure provides a process for purifying high-molecular weight bacterial polysaccharides (e.g., cell wall polysaccharides), and polypeptide-polysaccharide conjugates thereof, suitable for use in immunogenic compositions.
    Type: Application
    Filed: August 9, 2023
    Publication date: January 4, 2024
    Inventors: Christopher R. BEHRENS, Paresh AGARWAL, Lu YIN, Peter T. DAVEY, Angie A. SEDRA
  • ANTI-CD46 ANTIBODIES AND METHODS OF USE
    Publication number: 20230383005
    Abstract: Disclosed herein are methods of treating a subject having a cancer characterized by a modification at biomarker 1q21, which comprises administering to the subject a therapeutically effective amount of an anti-CD46 antibody.
    Type: Application
    Filed: July 27, 2022
    Publication date: November 30, 2023
    Applicant: The Regents of the University of California
    Inventors: Bin Liu, Daniel W. Sherbenou, Blake T. Aftab, Yang Su, Christopher R. Behrens
  • Anti-CD46 antibodies and methods of use
    Patent number: 11434301
    Abstract: Disclosed herein are methods of treating a subject having a cancer characterized by a modification at biomarker 1q21, which comprises administering to the subject a therapeutically effective amount of an anti-CD46 antibody.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: September 6, 2022
    Assignee: The Regents of the University of California
    Inventors: Bin Liu, Daniel W. Sherbenou, Blake T. Aftab, Yang Su, Christopher R. Behrens
  • MACROPINOCYTOSING HUMAN ANTI-CD46 ANTIBODIES AND TARGETED CANCER THERAPEUTICS
    Publication number: 20200199245
    Abstract: In various embodiments human anti-CD46 antibodies that are internalizing and enter tumor cells via the macropinocytosis pathway are provided, as well as antibody-drug conjugates (ADCs) developed from these antibodies for diagnostic and/or therapeutic targeting of CD46-overexpressing tumors.
    Type: Application
    Filed: November 21, 2019
    Publication date: June 25, 2020
    Inventors: Bin Liu, Yang Su, Scott Bidlingmaier, Christopher R. Behrens, Namkyung Lee
  • CONJUGATED VACCINES
    Publication number: 20200054739
    Abstract: Methods for the production of immunogenic compositions containing a non-natural amino acid are disclosed. The non-natural amino acid can be a site for attachment of antigens, such as bacterial capsular polysaccharides, to make immunogenic conjugates. Bio-orthogonal attachment chemistry incorporated into the non-natural amino acids allows for more efficient and potent antigen presentation to the immune system, simplified purification, and more well-defined structure of these semi-synthetic immunogens.
    Type: Application
    Filed: July 1, 2019
    Publication date: February 20, 2020
    Inventors: Jeffery C. FAIRMAN, Jon H. HEINRICHS, Wei CHAN, Olivier Jean Gérard MARCQ, Christopher R. Behrens
  • Macropinocytosing human anti-CD46 antibodies and targeted cancer therapeutics
    Patent number: 10533056
    Abstract: In various embodiments human anti-CD46 antibodies that are internalizing and enter tumor cells via the macropinocytosis pathway are provided, as well as antibody-drug conjugates (ADCs) developed from these antibodies for diagnostic and/or therapeutic targeting of CD46-overexpressing tumors.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: January 14, 2020
    Assignee: The Regents of the University of California
    Inventors: Bin Liu, Yang Su, Scott Bidlingmaier, Christopher R. Behrens, Namkyung Lee
  • ANTI-CD46 ANTIBODIES AND METHODS OF USE
    Publication number: 20190276553
    Abstract: Disclosed herein are methods of treating a subject having a cancer characterized by a modification at biomarker 1q21, which comprises administering to the subject a therapeutically effective amount of an anti-CD46 antibody.
    Type: Application
    Filed: November 10, 2017
    Publication date: September 12, 2019
    Inventors: Bin Liu, Daniel W. Sherbenou, Blake T. Aftab, Yang Su, Christopher R. Behrens
  • MACROPINOCYTOSING HUMAN ANTI-CD46 ANTIBODIES AND TARGETED CANCER THERAPEUTICS
    Publication number: 20170362330
    Abstract: In various embodiments human anti-CD46 antibodies that are internalizing and enter tumor cells via the macropinocytosis pathway are provided, as well as antibody-drug conjugates (ADCs) developed from these antibodies for diagnostic and/or therapeutic targeting of CD46-overexpressing tumors.
    Type: Application
    Filed: September 10, 2015
    Publication date: December 21, 2017
    Inventors: BIN LIU, Yang Su, Scott Bidlingmaier, Christopher R. Behrens, Namkyung Lee